<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003759</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066883</org_study_id>
    <secondary_id>ANTHRA-A9701/ID97-038</secondary_id>
    <secondary_id>MDA-ID-97038</secondary_id>
    <nct_id>NCT00003759</nct_id>
  </id_info>
  <brief_title>AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer</brief_title>
  <official_title>Intravesical Treatment of Superficial Bladder Cancer Characterized on the Basis of the Tumor Markers p53 and pRb</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anthra Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Biological therapies such as BCG use different ways to stimulate&#xD;
      the immune system and stop cancer cells from growing. It is not yet known whether AD 32 is&#xD;
      more effective with or without BCG after surgery for superficial bladder cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of AD 32 with or without BCG&#xD;
      after surgery in treating patients who have newly diagnosed or recurrent superficial bladder&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Evaluate the efficacy of peri-operative intravesical AD 32 alone or supplemented with&#xD;
           BCG in patients with newly diagnosed or recurrent superficial bladder cancer&#xD;
           characterized as either high risk or low risk based on the tumor markers p53 and pRb.&#xD;
&#xD;
        -  For low-risk patients, assess the efficacy of peri-operative AD 32 in preventing tumor&#xD;
           recurrence.&#xD;
&#xD;
        -  For high-risk patients, assess the efficacy of combined intravesical therapy with AD 32&#xD;
           administered within 8 hours after transurethral resection along with BCG in decreasing&#xD;
           the incidence of tumor progression.&#xD;
&#xD;
        -  Evaluate systemic exposure and urine recovery of AD 32 through pharmacokinetic analysis&#xD;
           in a subset of patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label study.&#xD;
&#xD;
      All patients undergo complete transurethral resection to remove bladder tumors. AD 32 is&#xD;
      administered by catheter into the bladder within 8 hours after surgery. Patients must hold&#xD;
      the AD 32 in the bladder for 90 minutes.&#xD;
&#xD;
      After pathological and tumor marker analysis, patients are assigned to the low or high-risk&#xD;
      group as defined by their p53 and pRb phenotype.&#xD;
&#xD;
        -  Low risk: Patients with carcinoma in situ receive BCG by catheter into the bladder once&#xD;
           weekly for 6 weeks beginning 7-21 days after treatment with AD 32. Patients assigned to&#xD;
           the low-risk group who do not have carcinoma in situ receive no further treatment.&#xD;
&#xD;
        -  High-risk: Patients also receive BCG once weekly for 6 weeks and then once weekly for 3&#xD;
           weeks at 3 months, 6 months, and then every 6 months for a total of 3 years after the&#xD;
           first BCG treatment.&#xD;
&#xD;
      All patients undergo cystoscopy every 3 months for the first year and then every 6 months for&#xD;
      the next 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 200 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1998</start_date>
  <completion_date type="Actual">November 2002</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Bladder Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valrubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Newly diagnosed or recurrent (at least 2 occurrences within 12 months) Ta, multifocal&#xD;
             Ta (at least 2 visible tumors), or stage T1 bladder cancer&#xD;
&#xD;
               -  No carcinoma in situ (Tis) only&#xD;
&#xD;
               -  No T2 or greater tumors&#xD;
&#xD;
          -  No evidence of upper tract (ureter or renal pelvic) transitional cell carcinoma based&#xD;
             on intravenous pyelogram performed within 4 months of the TURB&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  SWOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 3,500/mm3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, carcinoma in situ of the cervix, or superficial&#xD;
             transitional cell carcinoma of the bladder&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent biological response modifiers&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin P. Dinney, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2002</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 17, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2003</study_first_posted>
  <last_update_submitted>January 30, 2013</last_update_submitted>
  <last_update_submitted_qc>January 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2013</last_update_posted>
  <keyword>stage 0 bladder cancer</keyword>
  <keyword>stage I bladder cancer</keyword>
  <keyword>recurrent bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valrubicin</mesh_term>
    <mesh_term>BCG Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

